Discovery and bio-optimization of human antibody therapeutics using the XenoMouse®transgenic mouse platform-Reference-Cited by-同舟云学术

Discovery and bio-optimization of human antibody therapeutics using the XenoMouse®transgenic mouse platform

Published:2016-02-10 Issue:1 Volume:270 Page:51-64
ISSN:0105-2896
Container-title:Immunological Reviews
language:en
Short-container-title:Immunol Rev

Author:

Foltz Ian N.¹,Gunasekaran Kannan²,King Chadwick T.¹

Affiliation:

1. Amgen British Columbia; Burnaby BC Canada

2. Amgen Inc.; Thousand Oaks CA USA

Funder

Amgen

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imr.12409/fullpdf

Reference73 articles.

1. Reichert JM Therapeutic monoclonal antibodies approved or in review in the European Union or United States https://www.antibodysociety.org/news/approved_mabs.php

2. Transgenic mouse strains as platforms for the successful discovery and development of human therapeutic monoclonal antibodies;Green;Curr Drug Discov Technol,2014

3. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates;Chan;Proc Natl Acad Sci U S A,2009

4. Kinetic analysis of unpurified native antigens available in very low quantities and concentrations;Rathanaswami;Anal Biochem,2011

5. Roskos L Foltz I King C Amgen Fremont, Inc, Antibodies directed to parathyroid hormone (PTH) and uses thereof

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies;ImmunoHorizons;2023-12-01

2. Therapeutic monoclonal antibodies with a focus on hereditary angioedema;Allergology International;2023-01

3. Characterization of an Anti-CD70 Half-Life Extended Bispecific T-Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys;Toxicological Sciences;2022-05-18

4. CellCelector™ as a platform in isolating primary B cells for antibody discovery;Antibody Therapeutics;2022-01-01

5. Biologika in der pädiatrischen Rheumatologie;Pädiatrische Rheumatologie;2022